Laboratoires Fournier Sa

Abbvie Inc.

Laboratories Fournier S.a.

Didier Thomas

Michel Bondoux

Véronique Barberousse

Martine Barth

Vincent Peyrou

Shuhui Chen

Wentao Wu

Adrian Hobson

Michael M Friedman

Pierre Dodey

Maria A Argiriadi

Jianfei Wang

Eric C Breinlinger

Dawn M George

Dominique Bonafoux

Jean-Michel Luccarini

Christine Massardier

Fabrice Guillier

Guillaume Crosnier

Dominique Potin

Linlin Dai

Jeremy Edmunds

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof

The invention relates to novel 5-thioxylose compounds, preferably derivatives of the 5-thioxylopyranose type, to the process for their preparation and to their use as active principles of drugs intended especially for the treatment or prevention of thrombosis or cardiac insufficiency.

Compounds derived from 5-thioxylose and their use in therapeutics

The invention relates to new compounds of 5-thioxilose, preferably derivatives of the 5-thioxilopyranose type, and to a method for preparing the same and their use as the active ingredient of drugs mainly intended for treating or inhibiting thrombosis or heart failure or thromboembolic diseases.

Derivatives of 5-thioxylopyranose and use of same for treatment

Compounds of 5-thioxylopyranose, preferably derivatives of the 5-thioxilopyranose type, a method for preparing such compounds, and the use of such compounds as an active ingredient in pharmaceutical compositions which are useful, in particular, for treating or inhibiting thrombosis or heart failure or thromboembolic disease states.

5-thioxylopyranose compounds

5-thioxylose compounds, especially 5-thioxylopyranose compounds, a process for their preparation, and their use for treating and/or inhibiting thromboses, especially venous thromboses. The compounds correspond to formula I: in which the pentapyranosyl group represents a free or substituted 5-thio-&#x3b2;-D-xylopyranosyl group; R', R&#x2033; and R&#x2032;&#x2033; each independently represent a hydrogen atom, a C-Cacyl group, or two adjacent ones of them form a 1-methylethylidene bridge; Xand Xeach represent carbon or nitrogen; Yand Yeach independently represent carbon, nitrogen, sulfur or oxygen, with the proviso that if Yrepresents oxygen or sulfur, then Yrepresents carbon or nitrogen; R, R, R, Rand Reach independently represent hydrogen, a COORgroup where Rrepresents hydrogen or a C-Calkyl group optionally substituted by a phenyl ring, a halogen atom or a &#x2014;COORgroup; a C-Calkoxy group; a C-Cacyl group; a benzoyl group or a phenyl ring; and the addition salts and/or active metabolites of such compounds.

5-Thioxylopyranose compounds

The present invention concerns novel benzenesulphonamide compounds, defined by formula I. Therapeutic compositions comprising the benzenesulphonamide compounds of the invention or salts thereof and methods for producing the benzenesulphonamide compounds of the invention are also disclosed. The benzenesulphonamide compounds of the invention or salts thereof are useful for treating pain, such as hyperalgesia and major algesia.

Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain

Growing community of inventors

Saint Apollinaire, France

Didier Thomas